Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
$4.72
+0.6%
$4.50
$4.06
$6.44
$51.28M0.330,956 shs14,887 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$2.57
-4.8%
$2.25
$1.60
$16.55
$190.77M1.111.03 million shs587,171 shs
Inogen, Inc. stock logo
INGN
Inogen
$6.44
-1.4%
$6.78
$5.70
$13.33
$173.15M1.63239,735 shs123,308 shs
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$5.43
-0.9%
$5.42
$3.50
$7.62
$175.24M0.542,272 shs50,544 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
+0.64%+4.19%+7.76%-12.59%-8.17%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-4.81%+7.53%+4.90%-7.55%-80.96%
Inogen, Inc. stock logo
INGN
Inogen
-1.38%-1.38%-9.68%-22.69%-20.49%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-0.91%-2.34%+5.85%-5.73%-27.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
N/AN/AN/AN/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.4163 of 5 stars
4.60.00.00.02.42.50.6
Inogen, Inc. stock logo
INGN
Inogen
3.9602 of 5 stars
3.03.00.03.92.01.71.3
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.6607 of 5 stars
3.63.00.00.01.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
0.00
N/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.50386.38% Upside
Inogen, Inc. stock logo
INGN
Inogen
2.00
Hold$9.5047.52% Upside
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
3.25
Buy$10.7597.97% Upside

Current Analyst Ratings Breakdown

Latest APT, TLSI, CATX, and INGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Inogen, Inc. stock logo
INGN
Inogen
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Moderate Buy$12.00
5/14/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
5/8/2025
Inogen, Inc. stock logo
INGN
Inogen
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$10.00 ➝ $7.00
4/9/2025
Inogen, Inc. stock logo
INGN
Inogen
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/7/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $10.00
3/31/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/28/2025
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/27/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.00
3/26/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
3/19/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
$58.18M0.88$0.37 per share12.80$5.29 per share0.89
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$1.43M133.40N/AN/A$2.67 per share0.96
Inogen, Inc. stock logo
INGN
Inogen
$339.96M0.51N/AN/A$8.79 per share0.73
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
$32.14M5.45N/AN/A($0.98) per share-5.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
$4.19M$0.3712.76N/A6.99%6.70%5.76%N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)
Inogen, Inc. stock logo
INGN
Inogen
-$102.45M-$1.15N/AN/AN/A-15.89%-27.38%-16.77%8/5/2025 (Estimated)
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$59.04M-$1.12N/AN/AN/A-206.24%N/A-236.83%8/13/2025 (Estimated)

Latest APT, TLSI, CATX, and INGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million
5/7/2025Q1 2025
Inogen, Inc. stock logo
INGN
Inogen
-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 million
3/27/2025Q4 2024
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
-$0.35-$0.35N/A-$0.40$8.12 million$8.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
Inogen, Inc. stock logo
INGN
Inogen
N/AN/AN/AN/AN/A
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
N/A
19.00
11.21
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
Inogen, Inc. stock logo
INGN
Inogen
N/A
2.66
2.34
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
N/A
2.40
2.00

Institutional Ownership

CompanyInstitutional Ownership
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
22.69%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
Inogen, Inc. stock logo
INGN
Inogen
89.94%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
2.58%

Insider Ownership

CompanyInsider Ownership
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
15.00%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.52%
Inogen, Inc. stock logo
INGN
Inogen
1.46%
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
27.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
12010.86 million9.46 millionOptionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
Inogen, Inc. stock logo
INGN
Inogen
1,03026.89 million23.58 millionOptionable
TriSalus Life Sciences, Inc. stock logo
TLSI
TriSalus Life Sciences
10632.27 million20.49 millionNot Optionable

Recent News About These Companies

Roth Capital Issues Pessimistic Estimate for TLSI Earnings
Cantor Fitzgerald Has Negative View of TLSI FY2025 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alpha Pro Tech stock logo

Alpha Pro Tech NYSE:APT

$4.72 +0.03 (+0.64%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$4.55 -0.17 (-3.58%)
As of 05/30/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$2.57 -0.13 (-4.81%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$2.57 +0.00 (+0.04%)
As of 05/30/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Inogen stock logo

Inogen NASDAQ:INGN

$6.44 -0.09 (-1.38%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$6.66 +0.22 (+3.34%)
As of 05/30/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

TriSalus Life Sciences stock logo

TriSalus Life Sciences NASDAQ:TLSI

$5.43 -0.05 (-0.91%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$5.09 -0.34 (-6.26%)
As of 05/30/2025 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.